-
-
-
-
-
-
-
Immunitybio Inc (IBRX) PT Raised to $5 at Piper Sandler
-
-
-
-
-
-
-
National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome
-
-
-
-
-
-
-
ImmunityBio (IBRX) Announces FDA Acceptance of Biologics License Application for N-803
-
-
15,740 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

